Human Insulin Market Research Report – Forecast to 2023

Human Insulin Market Research Report – Forecast to 2023

ID: MRFR/HC/0350-HCRR | June, 2018 | Region: Global | 110 pages | Half-Cooked Research Reports

Human Insulin Market Research Report: Information by Type (Traditional Human Insulin and Modern Human Insulin), by Indication (Type 1 Diabetes and Type 2 Diabetes), and by End-User (Hospitals and Clinics and Research Institutes)- Global Forecast Till 2023


Market scenario


Human insulin is synthetic insulin manufactured in laboratories by growing the insulin protein with the help of E. coli bacteria. The global human insulin market is driven by the increasing prevalence and occurrence of Diabetes Mellitus (DM) and the increasing demand for human insulin. Additionally, the increasing technological innovations and the rising awareness and screening for diabetes mellitus also drive the market. Growing emphasis on diabetes management including new treatment options and rising geriatric population are various other factors that accelerate the growth of the market.


The global Human Insulin Market is expecting a healthy growth at a CAGR of 12.1% during forecast period.


Segmentation


The global human insulin market is segmented by type, indication, and end-users.


On the basis of type, it is segmented into accessories and devices.


On the basis of methods, it is segmented into traditional human insulin and modern human insulin.


On the basis of applications, it is segmented into type 1 diabetes and type 2 diabetes.


On the basis of end-users, it is segmented hospitals, forensic laboratories, research centers, and others.


Market Assessment


 human insulin market


Source; World Health Organization (WHO, white paper, company presentation, annual reports


Intended Audience



  • Research and Development (R&D) Companies

  • Insulin & Genomic Industries

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Figure 1- Global Human Insulin Market, by Region


 Human Insulin Market by Region


Source: Annual reports, press release, white paper, company presentation


Regional analysis


America is the largest market for human insulin. The growth of the market is driven by the inclination towards quality healthcare, increase in healthcare spending, and the presence of leading players. The U.S. is the largest market followed by Canada. South America is expected to be the fastest growing regions. Additionally, the increased funding for research and development activities by major players in the market is also expected to boost the market growth during the review period.


The European market for human insulin is driven by research funding in diabetes diagnosis and treatment and presence of huge population suffering from diabetes. In Germany, the market is driven by the increasing government support for research and development activities and a huge demand for human insulin. The increasing prevalence of obesity and unhealthy lifestyle of the people further increase the risk of diabetes among the European population.


In Asia Pacific, the human insulin market is fueled by the rising awareness of human insulin and a huge population base. China, Japan, and India are the major contributors to the growth of the market due to improvement in disease diagnosis and treatment services and development of the healthcare infrastructure. Furthermore, the presence of huge geriatric population diagnosed with diabetes also fuels the growth of the market in countries such as India and China in Asia Pacific.  The World Health Organization stated that in 2016, 10% of the adults were diagnosed with diabetes and type 2 diabetes which are found to be the most prevalent types of diabetes in China. The rising prevalence is due to the unhealthy lifestyle of people and lack of physical activities. Further, non-communicable diseases including diabetes are a major health threat contributing to 80% of the overall disease in China. Being the hub of diabetes, India is the largest and fastest growing market, with the majority of people facing the problem of obesity and related diseases.


In the Middle East & Africa, the market exhibits the growth owing to the rising demand for treatment services and need for primary care services. In countries such as United Arab Emirates (U.A.E.), Saudi Arabia, and Oman the availability of specialty care services and changing lifestyles of the people are the major drivers for the growth of the market. In Africa, poor economic condition and less development in medical facilities also determine the demand for diagnosis and treatment services.


Key players


Some of the major players in the global human insulin market are Biocon Ltd, Tonghua Dongbao Pharmaceuticals Co., Ltd., ADOCIA, Merck & Co, Julphar, Pfizer, Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Oramed Pharmaceuticals, Inc, Novo Nordisk A/S, and Sanofi.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Human Insulin Market, by Type

6.1 Introduction

6.2 Traditional Human Insulin

6.2.1 Market Estimates & Forecast, 2017–2023

6.3 Modern Human Insulin

6.3.1 Market Estimates & Forecast, 2017–2023

7. Global Human Insulin Market, by Indication

7.1 Introduction

7.2 Type 1 Diabetes

7.2.1 Market Estimates & Forecast, 2017–2023

7.3 Type 2 Diabetes

7.3.1 Market Estimates & Forecast, 2017–2023

8. Global Human Insulin Market, by End-User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2017–2023

8.3 Research Institutes

8.3.1 Market Estimates & Forecast, 2017–2023

9. Global Human Insulin Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Biocon Ltd

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.2 Tonghua Dongbao Pharmaceuticals Co., Ltd.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.3 Merck & Co.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.4 ADOCIA

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.5 Pfizer

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Bristol-Myers Squibb Company

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 GlaxoSmithKline

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Human Insulin Industry

14 Appendix





LIST OF TABLES

Table 1 Human Insulin Industry Synopsis, 2017–2023

Table 2 Global Human Insulin Market Estimates & Forecast, 2017–2023, (USD Million)

Table 3 Global Human Insulin Market, by Region, 2017–2023, (USD Million)

Table 4 Global Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 5 Global Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 6 Global Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 7 North America Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 8 North America Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 9 North America Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 10 U.S. Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 11 U.S. Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 12 U.S. Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 13 Canada Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 14 Canada Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 15 Canada Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 16 South America Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 17 South America Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 18 South America Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 19 Europe Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 20 Europe Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 21 Europe Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 22 Western Europe Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 23 Western Europe Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 24 Western Europe Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 25 Eastern Europe Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 26 Eastern Europe Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 27 Eastern Europe Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 28 Asia Pacific Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 29 Asia Pacific Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 30 Asia Pacific Human Insulin Market, by End-User, 2017–2023, (USD Million)

Table 31 Middle East & Africa Human Insulin Market, by Type, 2017–2023, (USD Million)

Table 32 Middle East & Africa Human Insulin Market, by Indication, 2017–2023, (USD Million)

Table 33 Middle East & Africa Human Insulin Market, by End-User, 2017–2023, (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Human Insulin Market

Figure 3 Segmentation Market Dynamics for Human Insulin Market

Figure 4 Global Human Insulin Market Share, by Type 2016

Figure 5 Global Human Insulin Market Share, by Indication 2016

Figure 6 Global Human Insulin Market Share, by End-User, 2016

Figure 7 Global Human Insulin Market Share, by Region, 2016

Figure 8 North America Human Insulin Market Share, by Country, 2016

Figure 9 Europe Human Insulin Market Share, by Country, 2016

Figure 10 Asia Pacific Human Insulin Market Share, by Country, 2016

Figure 11 Middle East & Africa Human Insulin Market Share, by Country, 2016

Figure 12 Global Human Insulin Market: Company Share Analysis, 2016 (%)

Figure 13 Biocon Ltd: Key Financials

Figure 14 Biocon Ltd: Segmental Revenue

Figure 16 Biocon Ltd: Geographical Revenue

Figure 17 Tonghua Dongbao Pharmaceuticals Co., Ltd.: Key Financials

Figure 18 Tonghua Dongbao Pharmaceuticals Co., Ltd.: Segmental Revenue

Figure 19 Tonghua Dongbao Pharmaceuticals Co., Ltd.: Geographical Revenue

Figure 20 GlaxoSmithKline plc: Key Financials

Figure 21 GlaxoSmithKline plc: Segmental Revenue

Figure 22 GlaxoSmithKline plc: Geographical Revenue

Figure 23 ADOCIA, INC.: Key Financials

Figure 24 ADOCIA, INC.: Segmental Revenue

Figure 25 ADOCIA, INC.: Geographical Revenue



Figure 26 Pfizer: Key Financials

Figure 27 Pfizer: Segmental Revenue

Figure 28 Pfizer: Geographical Revenue

Figure 29 Bristol-Myers Squibb Company: Key Financials

Figure 30 Bristol-Myers Squibb Company: Segmental Revenue

Figure 31 Bristol-Myers Squibb Company: Geographical Revenue